Vilanterol is FDA approved for treatment of:
**Core Concept**
Vilanterol is a long-acting beta2-adrenergic receptor agonist (LABA) used in the management of chronic obstructive pulmonary disease (COPD) and asthma. It works by stimulating the beta2 receptors in the bronchial smooth muscle, leading to bronchodilation and improved lung function.
**Why the Correct Answer is Right**
Vilanterol, when used in combination with inhaled corticosteroids (ICS), has been shown to improve lung function and reduce exacerbations in patients with COPD. The LABA component of vilanterol helps to overcome the airway obstruction and improve symptoms in patients with COPD. This is particularly useful in patients who are at high risk of exacerbations or have a history of frequent exacerbations.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as vilanterol is not primarily used for the treatment of asthma. While it may be used in combination with ICS for the treatment of asthma, it is not the primary indication.
**Option B:** This option is incorrect as vilanterol is not used for the treatment of heart failure. Although beta2 agonists can have some effects on the cardiovascular system, vilanterol is not indicated for the treatment of heart failure.
**Option C:** This option is incorrect as vilanterol is not used for the treatment of hypertension. While beta2 agonists can have some effects on blood pressure, vilanterol is not indicated for the treatment of hypertension.
**Clinical Pearl / High-Yield Fact**
It's essential to remember that LABAs like vilanterol should be used in combination with ICS in patients with COPD or asthma. This combination therapy has been shown to improve lung function and reduce exacerbations in these patients.
**Correct Answer:** C.